30 results about "BLOOD URINE" patented technology

The invention relates to a Chinese patent medicine with plants as raw materials, in particular to a traditional Chinese medicine composition for treating nephritic hematuria. The medicine composition is composed of active components and pharmaceutically acceptable auxiliary materials, and is characterized in that the active components are prepared from the following raw medicines in parts by weight: 3-9 parts of glossy privet fruit, 3-9 parts of burdock fruit, 3-9 parts of yerbadetajo, 9-27 parts of cogongrass rhizome, 6-18 parts of verbena, 6-12 parts of oldenlandia diffusa, 6-12 parts of pyrrosia lingua, 12-24 parts of motherwort, 6-12 parts of arborvitae tops and 3-9 parts of gromwell. All medicines in the prescription provided by the invention are compatible and play the efficacies of nourishing the kidney, removing heat from the blood, removing blood stasis, arresting bleeding, detoxifying and removing dampness.

The invention discloses a medicinal composition for treating hypertensive nephropathy. The medicinal composition is composed of the following ingredients: fructus chebulae, fructus gardeniae, fructustoosendan, flos carthami, folium eriobotryae, lacca, radix aconiti kusnezoffii, resin commiphorae muakulis(guggulum), fructus amomi rotundus, white soybeans, all-grass of oxytropis myriophylla, and the like. The medicinal composition provided by the invention can obviously reduce urine protein and urine microalbumin, and has the total effective rate achieving 90% when used for treating proteinuria, after 24h of treatment for urine protein, urine microalbumin, serum creatinine, urea nitrogen, blood and urine beta2-MG, the result shows that the medicinal composition has the obvious efficiency intreating hypertensive nephropathy, and can obviously improve proteinuria, and protect the kidney function.

The invention discloses a kit based on a single particle size and capable of simultaneously detecting retinol-binding protein in serum and urine samples. The kit includes reagent R1, reagent R2, calibrator A, calibrator B, and the reagent R2 includes a latex-polyclonal antibody cross-linked product and a reagent R2 buffer, the latex-polyclonal antibody cross-linked product accounts for 0.05-1.0% by mass of the reagent R2, and the reagent R2 buffer component is: 50-120mM Hepes buffer, 0.1% Proclin 300, 1-5% sucrose, 1-5% NaCl, 0.1-1% Triton, the rest is purified water, pH is 6.5-8.5. The kit of the present invention has the advantages of simultaneous measurement of hematuria, simple operation, high sensitivity, wide linear range, and low cost (not only reflected in the fact that only one particle size and polyclonal antibody can meet the detection requirements, but also in the preparation of latex-multiple When cloning antibodies, only one centrifugation can meet the labeling requirements) and facilitate the advantages of marketing. At the same time, the detection kit is compatible with most biochemical detection equipment on the market and can directly enter the market.

The invention discloses an LC-MS / MS analysis method for detecting morphinane alkaloid in whole blood and urine. The conditions of LC-MS and MS are separately as follows: 1) LC-MS chromatographic conditions: the mobile phase is composed of A and B, wherein A is an aqueous solution containing 2mmol / L of ammonium formate and 0.05% (v / v) of formic acid, B is acetonitrile containing 2mmol / L of ammonium formate and 0.05% (v / v) of formic acid, the volume ratio of A to B is 90:10; the column temperature is 45 DEG C; the flow rate is 0.2mL / min; the sampling volume is 10mu L; and 2) MS conditions: the detection mode adopts multiple reaction monitoring (MRM); the scanning mode adopts positive ion scanning; the electrospray voltage is 3200V; the atomization air flow rate is N2 600L / hr; the cone gas glow is N2 50L / hr; the ion source temperature is 105 DEG C; the collision gas is argon; and the internal standard adopts morphine-d3. The morphinane alkaloid contains morphine-3-beta-D-glucuronide, morphine, O6-monoacetylmorphine and codeine. The analysis method of the invention adopts solid phase extraction to purify the sample, thus the qualitative and quantitative measurements become more accurate; by adopting different elution and elution conditions, the obtained rate of recovery can be the optimal; and after the sample is added, methanol is used for further elution, thus simplifying the experimental procedures and reducing the analysis time.

The invention relates to a drug for treating chronic kidney disease proteinuria, which is a capsule prepared as follows: the materials are astragalus, Oriental Waterplantain Rhizome, Chinese Magnolivine Fruit, fried foxnut and node of lotus rhizome, which are added to water to be decocted, and the decoction solution is concentrated and dried. The drug has the advantages of kidney invigorating, diuresis inducing and stranguria treating, blood activating and stasis removing, swelling reducing and pain alleviating, heat-clearing and detoxifying, body fluid regenerating and thirst quenching, darrhea relieving, cough relieving and bleeding stopping, which has the function of body immunity regulation and reinforcing, and is suitable for the patient with chronic kidney disease and chronic renal failure proteinuria; the drug can effectively reduce proteinuria, increase plasma albumin, reduce the pathological changes of kidney and improve hemorheology indexes, which has a certain controlling effect on hematuria and proteinuria. In clinical verification, the drug has the advantages of fast therapeutic effect, good efficacy and small side effect.

The invention provides a method for quantitatively detecting sarcosine content and a reaction kit, the method comprising steps: S1 preparing sarcosine solutions with different concentrations, adding a reaction reagent to the solution to completely react sarcosine and hydrogen peroxide ; S2 measures the fluorescence emission spectrum of the fluorescent dimer of the reaction product in S1 respectively, and draws the sarcosine concentration-fluorescence intensity relationship curve; S3 uses the method as described in S1 to make the unknown sarcosine sample occur as described in S1 For the reaction, measure the fluorescence emission spectrum of the reaction product to obtain the fluorescence intensity data, and compare the sarcosine concentration-fluorescence intensity relationship curve to obtain the content of the unknown sarcosine sample. The reaction kit components of the present invention include p-cresol or p-hydroxyphenylacetic acid solution, sarcosine oxidase, peroxidase, and alkaline buffer. The method of the invention is very suitable for mass analysis and detection of trace amounts of sarcosine in urine samples or blood samples.